Share on LinkedInShare on LinkedIn

ARTICLE · 12 APRIL 2022

PMPRB Update: PMPRB Is Accepting Intervener Leave Applications For SOLIRIS Re-hearing

McCarthy Tétrault
McCarthy Tétrault
Contributor
McCarthy Tétrault

McCarthy Tétrault

Built on a unique model of collaboration, innovation and efficiency, McCarthy Tétrault delivers...

View firm profile
Explore more from McCarthy Tétrault

On April 1, 2022, Canada's Patented Medicine Prices Review Board ("PMPRB") announced it will hold a public re-hearing concerning the price of Alexion Pharmaceuticals' patented medicine SOLIRIS (eculizumab).

CanadaIntellectual Property

On April 1, 2022, Canada's Patented Medicine Prices Review Board ("PMPRB") announced it will hold a public re-hearing concerning the price of Alexion Pharmaceuticals' patented medicine SOLIRIS (eculizumab). The Board further announced that it will be accepting intervener applications until May 1, 2022.1

As previously reported, Alexion markets the medicine SOLIRIS, a breakthrough treatment for two rare and life-threatening blood-related disorders. In 2017, the PMPRB issued a decision finding that Alexion sold SOLIRIS at an excessive price contrary to the Patent Act, and ordered Alexion to forfeit excess revenues earned between 2009 and 2017.2 The Board relied on the fact that the Canadian list price of SOLIRIS was higher than the price in one of seven comparator countries specified in the Patented Medicines Regulations. According to the PMPRB, the price of SOLIRIS had to be lower than that of all seven comparator countries to avoid being excessive, departing from

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from